NOBBIO, LUCILLA
 Distribuzione geografica
Continente #
EU - Europa 7.990
AS - Asia 953
NA - Nord America 690
Continente sconosciuto - Info sul continente non disponibili 86
SA - Sud America 66
AF - Africa 13
OC - Oceania 1
Totale 9.799
Nazione #
IT - Italia 7.847
US - Stati Uniti d'America 627
SG - Singapore 382
CN - Cina 227
VN - Vietnam 171
BD - Bangladesh 70
FR - Francia 65
HK - Hong Kong 38
BR - Brasile 35
CA - Canada 26
MX - Messico 15
JP - Giappone 14
AR - Argentina 13
FI - Finlandia 10
DE - Germania 9
ID - Indonesia 9
IN - India 9
NL - Olanda 9
CH - Svizzera 8
CO - Colombia 7
IQ - Iraq 7
JM - Giamaica 7
GB - Regno Unito 6
BE - Belgio 5
ES - Italia 5
GT - Guatemala 4
ZA - Sudafrica 4
AT - Austria 3
CL - Cile 3
EC - Ecuador 3
IL - Israele 3
LV - Lettonia 3
MY - Malesia 3
PL - Polonia 3
SA - Arabia Saudita 3
CR - Costa Rica 2
EG - Egitto 2
GR - Grecia 2
HN - Honduras 2
IE - Irlanda 2
JO - Giordania 2
LT - Lituania 2
NP - Nepal 2
PK - Pakistan 2
PR - Porto Rico 2
PT - Portogallo 2
RU - Federazione Russa 2
SE - Svezia 2
VE - Venezuela 2
AL - Albania 1
AU - Australia 1
BB - Barbados 1
BO - Bolivia 1
BS - Bahamas 1
CG - Congo 1
CY - Cipro 1
DM - Dominica 1
DO - Repubblica Dominicana 1
DZ - Algeria 1
GE - Georgia 1
HR - Croazia 1
KE - Kenya 1
KR - Corea 1
KW - Kuwait 1
LC - Santa Lucia 1
LK - Sri Lanka 1
MA - Marocco 1
MD - Moldavia 1
MK - Macedonia 1
MM - Myanmar 1
MZ - Mozambico 1
PS - Palestinian Territory 1
PY - Paraguay 1
SC - Seychelles 1
TH - Thailandia 1
TN - Tunisia 1
TR - Turchia 1
TW - Taiwan 1
UA - Ucraina 1
UY - Uruguay 1
UZ - Uzbekistan 1
Totale 9.713
Città #
Genova 4.255
Genoa 2.162
Rapallo 762
Vado Ligure 553
Singapore 191
San Jose 174
Ashburn 60
Lauterbourg 54
Hanoi 49
Ho Chi Minh City 46
Hong Kong 36
New York 33
Beijing 31
Rome 20
Bordighera 17
Los Angeles 16
Santa Clara 16
Council Bluffs 15
Milan 15
Tokyo 13
Helsinki 10
Biên Hòa 9
Chicago 9
Buffalo 8
Mexico City 8
Houston 7
Montreal 7
Zurich 7
Baghdad 6
Da Nang 6
Frankfurt am Main 6
Haiphong 6
Kingston 6
San Francisco 6
Toronto 6
Turin 6
Amsterdam 5
Atlanta 5
Bologna 5
Orem 5
Phoenix 5
Augusta 4
Guangzhou 4
Guatemala City 4
Paris 4
São Paulo 4
Brooklyn 3
Bắc Ninh 3
Can Tho 3
Changsha 3
Dallas 3
Dhaka 3
Eugene 3
Johannesburg 3
Las Vegas 3
Naples 3
Padua 3
Philadelphia 3
Riga 3
Shanghai 3
Shenzhen 3
Vĩnh Tường 3
Warsaw 3
Wilmington 3
Abilene 2
Albuquerque 2
Anchorage 2
Anderlecht 2
Arroyo Grande 2
Athens 2
Brussels 2
Calgary 2
Cali 2
Chanhassen 2
Charlotte 2
Chennai 2
City of London 2
Columbus 2
Da Lat 2
Dammam 2
Des Moines 2
Dublin 2
Durham 2
Edmonton 2
Fortaleza 2
Georgetown 2
Greenville 2
Havertown 2
Jaipur 2
Jakarta 2
Kalkaska 2
Kathmandu 2
Lahore 2
León 2
Lincoln 2
Marseille 2
Medellín 2
Memphis 2
Minneapolis 2
Nampa 2
Totale 8.802
Nome #
Experimental Charcot-Marie-Tooth type 1A: A cDNA microarrays analysis 224
Does parkin play a role in the peripheral nervous system? A family report 214
Sphingomyelin as a myelin biomarker in CSF of acquired demyelinating neuropathies 211
Early abnormalities in sciatic nerve function and structure in a rat model of Charcot-Marie-Tooth type 1A disease. 206
The diadenosine homodinucleotide P18 improves in vitro myelination in experimental Charcot-Marie-Tooth type 1A 201
Mycophenolate mofetil in dysimmune neuropathies: a preliminary study. 195
Axonal damage and demyelination in long-term dorsal root ganglia cultures from a rat model of Charcot-Marie-Tooth type 1A disease 191
Ascorbic acid in Charcot-Marie-Tooth disease type 1A (CMT-TRIAAL and CMT-TRAUK): a double-blind randomised trial. 190
Hyccin, the Molecule Mutated in the Leukodystrophy Hypomyelination and Congenital Cataract (HCC), Is a Neuronal Protein. 187
Different cellular and molecular mechanisms for early and late-onset myelin protein zero mutations 186
Alterations in the Arf6-regulated plasma membrane endosomal recycling pathway in cells overexpressing the tetraspan protein Gas3/PMP22 185
Alternative Splicing in the Human PMP22 Gene: Implications in CMT1A Neuropathy 182
Soluble Neuregulin1 is strongly up-regulated in the rat model of Charcot-Marie-Tooth 1A disease 181
Genetic Workup for Charcot–Marie–Tooth Neuropathy: A Retrospective Single-Site Experience Covering 15 Years 180
Underexpression of messenger RNA for peripheral myelin protein 22 in hereditary neuropathy with liability to pressure palsies 178
Impaired expression of ciliary neurotrophic factor in Charcot-Marie-Tooth type 1A neuropathy 174
Mitichondrial dysfunction in experimental Charcot-marie-Tooth type 1° (CMTIA) neuropathy: a possible key factor for the axonal degeneration 173
Impairment of PMP22 transgenic Schwann cells differentiation in culture: implications for Charcot-Marie-Tooth type 1A disease. 165
PMP22 transgenic dorsal root ganglia cultures show myelin abnormalities similar to those of human CMT1A. 164
The SPTLC1 p.S331 mutation bridges sensory neuropathy and motor neuron disease and has implications for treatment 163
Correlation among demyelination and axonal degeneration: a new trophic role for myelin sheath 163
Insulin treatment enhances expression of IGF-I in sural nerves of diabetic patients. 158
Mifepristone (RU 38486) influences expression of glycoprotein Po and morphological parameters at the level of rat sciatic nerve: In vivo observations . 155
Inherited Peripheral Neuropathies 154
A P2X7 antagonist improves muscle strength and motor distal amplitude in CMT1A rats: preliminary results from an in vivo trial 153
A multicenter, randomized, double-blind, placebo-controlled trial of long-term ascorbic acid treatment in Charcot-Marie-Tooth disease type 1A (CMT-TRIAAL): the study protocol 153
Diadenosine homodinucleotide products of ADP-ribosyl cyclases behave as modulators of the purinergic receptor P2X7. 149
Oxydative phosphorilation in sciatic nerve myelin and its impairment in a model of dysmyelinating peripheral neuropathy 147
P2X7 antagonists improve “in vitro” myelination in organotypic dorsal root ganglia (DRG) cultures from a rat model of CMT1A neuropathy 147
A P2X7 antagonist improves muscle strength and motor distal amplitude in CMT1A rats: preliminary results from an in vivo trial 145
P2X7-mediated increased intracellular calcium causes functional derangement in Schwann cells from rats with CMT1A neuropathy 145
Oxydative phosphorylation in sciatic nerve myelin and its impairment in a model of dysmyelinating peripheral neuropathy 144
Ebf Genes In Peripheral Nerve Myelination 143
Synaptopodin and 4 novel genes identified in primary sensory neurons. 143
P2X7 antagonism in experimental CMT1A: a potential therapeutic strategy 141
PMP22 messenger RNA levels in skin biopsies: Testing the effectiveness of a Charcot-Marie-Tooth 1A biomarker 139
The transcription factors EBF1 and EBF2 are positive regulators of myelination in Schwann cells 135
A novel mouse model of CMT1B identifies hyperglycosylation as a new pathogenetic mechanism 135
Ebf genes' silencing impairs myelin formation 132
Role of the P2X7 receptor in the altered calcium homeostasis of Schwann cells overexpressing peripheral myelin protein 22 131
P2X7 antagonists improve “in vitro” myelination in organotypic dorsal root ganglia (DRG) cultures from a rat model of CMT1A neuropathy 130
The diadenosine homodinucleotide P18 improvesin vitromyelination in experimental Charcot-Marie-Tooth type 1A 129
Tyrosine kinase A-Nerve Growth Factor receptor is antigenically present in dystrophic neurites from a variety of conditions but not in Alzheimer's disease. 128
Mitochondrial dysfunction in experimental Charcot-Marie-Tooth type 1A (CMT1A) neuropathy. 125
A P2X7 antagonist improves muscle strength and motor distal amplitude in CMT1A rats: preliminary results from an in vivo trial. 125
Effect of recombinant human nerve growth factor on cisplatin neurotoxicity in rats 124
P2X7 RECEPTOR IMPLICATION IN CHARCOT-MARIE-TOOTH TYPE 1A (CMT1A) 124
Neuroactive Steroid Levels in a transgenic rat model of CMT1A Neuropathy. 124
Energetic disfunction in CMT1A: role of myelin and neuron mitochondria 122
P2X7 TARGETING IMPROVES IN VITRO MYELINATION IN EXPERIMENTAL CHARCOT-MARIE-TOOTH TYPE 1A (CMT1A) 121
P2X7 overexpression is responsible for the increased intracellular calcium and functional derangement in Schwann cells from rats with Charcot-Marie-Tooth type 1A neuropathy. 118
Energetic metabolism of myelinated axons: a new correlation among axonal degeneration, demyelination and energy supply. 117
Energy supply and demyelinising diseases: a new trophic role of myelin sheath. 117
Vitamin C and Charcot-Marie-Tooth 1A: Pharmacokinetic considerations 117
P2X7 overexpression is responsible for the increased intracellular calcium and functional derangement in Schwann cells from rats with Charcot-Marie-Tooth type 1A neurophaty. 115
Mitochondrial dysfunction in experimental Charcot-Marie-Tooth type 1° (CMT1A) neuropathy. 115
Role of the P2X7 receptor in the altered calcium homeostasis of Schwann cells overexpressing peripheral myelin protein 22 (PMP22) 115
Mitochondrial dysfunction in experimental Charcot-Marie-Tooth type 1° (CMT1A) neuropathy. 110
Functional Characterization of Hyccin, a Novel Membrane Protein Involved in Central and Peripheral Myelination 110
DEVELOPMENT AND VALIDATION OF A BIOMARKERS PANEL TO CAPTURE PATHOPHYSIOLOGICAL HETEROGENEITY OF GBS AND CIDP PATIENTS 102
Mitochondrial dysfunction in experimental Charcot-Marie-Tooth type 1A (CMT1A) neuropathy. 102
Mitochondrial dysfunction in experimental Charcot-Marie-Tooth type 1° (CMT1A) neuropathy. 96
Increased [18F]DPA-714 Uptake in the Skeletal Muscle of SOD1G93A Mice: A New Potential of Translocator Protein 18 kDa Imaging in Amyotrophic Lateral Sclerosis 94
Neuropatie di Charcot-Marie-Tooth: dalla patologia alla patogenesi 82
Inherited neuropathies. 77
CSF sphingomyelin: a new biomarker of demyelination in the diagnosis and management of CIDP and GBS 75
Guillain barré syndrome of axonal type in a multple sclerosis patient: Fortuitous association or linked disorders? 66
null 48
Basic Pathological Mechanisms in Peripheral Nerve Diseases 47
Techniques for the standard histological and ultrastructural assessment of nerve biopsies 37
Selected items from the Charcot-Marie-Tooth (CMT) Neuropathy Score and secondary clinical outcome measures serve as sensitive clinical markers of disease severity in CMT1A patients 25
Totale 9.799
Categoria #
all - tutte 31.279
article - articoli 24.150
book - libri 0
conference - conferenze 6.674
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 455
Totale 62.558


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022756 16 69 51 86 20 48 44 186 32 63 31 110
2022/2023885 74 82 7 83 173 132 2 81 139 6 94 12
2023/2024494 31 51 15 63 36 85 58 39 22 10 23 61
2024/20251.426 96 83 52 104 167 126 111 272 53 48 154 160
2025/20262.470 372 71 133 160 422 176 359 110 150 239 123 155
2026/2027198 198 0 0 0 0 0 0 0 0 0 0 0
Totale 9.799